LZTR1: A promising adaptor of the CUL3 family (Review)

Zhang,Hui; Cao,Xinyi; Wang,Jian; Li,Qian; Zhao,Yiting; Jin,Xiaofeng

doi:10.3892/ol.2021.12825

LZTR1: A promising adaptor of the CUL3 family (Review)

Authors:
- Hui Zhang
- Xinyi Cao
- Jian Wang
- Qian Li
- Yiting Zhao
- Xiaofeng Jin
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology; Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, Zhejiang 315211, P.R. China
Published online on: May 29, 2021 https://doi.org/10.3892/ol.2021.12825
Article Number: 564
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The study of the disorders of ubiquitin‑mediated proteasomal degradation may unravel the molecular basis of human diseases, such as cancer (prostate cancer, lung cancer and liver cancer, etc.) and nervous system disease (Parkinson's disease, Alzheimer's disease and Huntington's disease, etc.) and help in the design of new therapeutic methods. Leucine zipper‑like transcription regulator 1 (LZTR1) is an important substrate recognition subunit of cullin‑RING E3 ligase that plays an important role in the regulation of cellular functions. Mutations in LZTR1 and dysregulation of associated downstream signaling pathways contribute to the pathogenesis of Noonan syndrome (NS), glioblastoma and chronic myeloid leukemia. Understanding the molecular mechanism of the normal function of LZTR1 is thus critical for its eventual therapeutic targeting. In the present review, the structure and function of LZTR1 are described. Moreover, recent advances in the current knowledge of the functions of LZTR1 in NS, glioblastoma (GBM), chronic myeloid leukemia (CML) and schwannomatosis and the influence of LZTR1 mutations are also discussed, providing insight into how LZTR1 may be targeted for therapeutic purposes.

View Figures

View References

1	Hershko A and Ciechanover A: The ubiquitin system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar : PubMed/NCBI
2	Mani RS: The emerging role of speckle-type POZ protein (SPOP) in cancer development. Drug Discov Today. 19:1498–1502. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zou T and Zhang J: Diverse and pivotal roles of neddylation in metabolism and immunity. FEBS J. Oct 6;s2020doi: 10.1111/febs.15584.
4	Petroski MD and Deshaies RJ: Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 6:9–20. 2005. View Article : Google Scholar : PubMed/NCBI
5	Asmar AJ, Beck DB and Werner A: Control of craniofacial and brain development by Cullin3-RING ubiquitin ligases: Lessons from human disease genetics. Exp Cell Res. 396:1123002020. View Article : Google Scholar : PubMed/NCBI
6	Achim W, Regina B, Nia T, Kaya DU and Michael R: Multisite dependency of an E3 ligase controls monoubiquitylation-dependent cell fate decisions. Elife. 7:e354072018. View Article : Google Scholar
7	Senft D, Qi J and Ronai ZA: Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat Rev Cancer. 18:69–88. 2018. View Article : Google Scholar : PubMed/NCBI
8	Rape M: Ubiquitylation at the crossroads of development and disease. Nat Rev Mol Cell Biol. 19:59–70. 2018. View Article : Google Scholar : PubMed/NCBI
9	Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, et al: Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature. 416:703–709. 2002. View Article : Google Scholar : PubMed/NCBI
10	Enchev RI, Schulman BA and Peter M: Protein neddylation: Beyond cullin-RING ligases. Nat Rev Mol Cell Biol. 16:30–44. 2015. View Article : Google Scholar : PubMed/NCBI
11	Wang Z, Liu P, Inuzuka H and Wei W: Roles of F-box proteins in cancer. Nat Rev Cancer. 14:233–247. 2014. View Article : Google Scholar : PubMed/NCBI
12	Teixeira LK and Reed SI: Ubiquitin ligases and cell cycle control. Annu Rev Biochem. 82:387–414. 2013. View Article : Google Scholar : PubMed/NCBI
13	Lipkowitz S and Weissman AM: RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer. 11:629–643. 2011. View Article : Google Scholar : PubMed/NCBI
14	Cornelius RJ, Ferdaus MZ, Nelson JW and McCormick JA: Cullin-Ring ubiquitin ligases in kidney health and disease. Curr Opin Nephrol Hypertens. 28:490–497. 2019. View Article : Google Scholar : PubMed/NCBI
15	Chen RH: Cullin 3 and its role in tumorigenesis. Adv Exp Med Biol. 1217:187–210. 2020. View Article : Google Scholar : PubMed/NCBI
16	Wu J, McCormick JA and Sigmund CD: Cullin-3: Renal and vascular mechanisms regulating blood pressure. Curr Hypertens Rep. 22:612020. View Article : Google Scholar : PubMed/NCBI
17	Wang P, Song J and Ye D: CRL3s: The BTB-CUL3-RING E3 ubiquitin Ligases. Adv Exp Med Biol. 1217:211–223. 2020. View Article : Google Scholar : PubMed/NCBI
18	Cornelius RJ, Yang CL and Ellison DH: Hypertension-causing cullin 3 mutations disrupt COP9 signalosome binding. Am J Physiol Renal Physiol. 318:F204–F208. 2020. View Article : Google Scholar : PubMed/NCBI
19	Jin X, Shi Q, Li Q, Zhou L, Wang J, Jiang L, Zhao X, Feng K, Lin T, Lin Z, et al: CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling. Leukemia. 34:1305–1314. 2020. View Article : Google Scholar : PubMed/NCBI
20	Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, et al: Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 44:685–689. 2012. View Article : Google Scholar : PubMed/NCBI
21	Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, et al NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program, : Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 44:1310–1315. 2012. View Article : Google Scholar : PubMed/NCBI
22	Jin X, Wang J, Gao K, Zhang P, Yao L, Tang Y, Tang L, Ma J, Xiao J, Zhang E, et al: Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer. PLoS Genet. 13:e10067482017. View Article : Google Scholar : PubMed/NCBI
23	Wei X, Fried J, Li Y, Hu L, Gao M, Zhang S and Xu B: Functional roles of Speckle-Type Poz (SPOP) protein in genomic stability. J Cancer. 9:3257–3262. 2018. View Article : Google Scholar : PubMed/NCBI
24	Cuneo MJ and Mittag T: The ubiquitin ligase adaptor SPOP in cancer. FEBS J. 286:3946–3958. 2019. View Article : Google Scholar : PubMed/NCBI
25	Jin X, Wang J, Li Q, Zhuang H, Yang J, Lin Z, Lin T, Lv Z, Shen L, Yan C, et al: SPOP targets oncogenic protein ZBTB3 for destruction to suppress endometrial cancer. Am J Cancer Res. 9:2797–2812. 2019.PubMed/NCBI
26	Wang Z, Song Y, Ye M, Dai X, Zhu X and Wei W: The diverse roles of SPOP in prostate cancer and kidney cancer. Nat Rev Urol. 17:339–350. 2020. View Article : Google Scholar : PubMed/NCBI
27	Song Y, Xu Y, Pan C, Yan L, Wang ZW and Zhu X: The emerging role of SPOP protein in tumorigenesis and cancer therapy. Mol Cancer. 19:22020. View Article : Google Scholar : PubMed/NCBI
28	Clark A and Burleson M: SPOP and cancer: A systematic review. Am J Cancer Res. 10:704–726. 2020.PubMed/NCBI
29	Maekawa M and Higashiyama S: The roles of SPOP in DNA damage response and DNA replication. Int J Mol Sci. 21:72932020. View Article : Google Scholar : PubMed/NCBI
30	Werner A, Iwasaki S, McGourty CA, Medina-Ruiz S, Teerikorpi N, Fedrigo I, Ingolia NT and Rape M: Cell-fate determination by ubiquitin-dependent regulation of translation. Nature. 525:523–527. 2015. View Article : Google Scholar : PubMed/NCBI
31	Li YR, Peng RR, Gao WY, Liu P, Chen LJ, Zhang XL, Zhang NN, Wang Y, Du L, Zhu FY, et al: The ubiquitin ligase KBTBD8 regulates PKM1 levels via Erk1/2 and Aurora A to ensure oocyte quality. Aging (Albany NY). 11:1110–1128. 2019. View Article : Google Scholar : PubMed/NCBI
32	Lührig S, Kolb S, Mellies N and Nolte J: The novel BTB-kelch protein, KBTBD8, is located in the Golgi apparatus and translocates to the spindle apparatus during mitosis. Cell Div. 8:32013. View Article : Google Scholar
33	Jiang T, Sánchez-Rivera F, Soto-Feliciano Y, Yang Q, Song CQ, Bhuatkar A, Haynes CM, Hemann MT and Xue W: Targeting de novo purine synthesis pathway via ADSL depletion impairs liver cancer growth by perturbing mitochondrial function. Hepatology. Dec 17–2020.(Epub ahead of print). doi: 10.1002/hep.31685. View Article : Google Scholar
34	Madden S and Itzhaki L: Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery. Biochim Biophys Acta Proteins Proteom. 1868:1404052020. View Article : Google Scholar : PubMed/NCBI
35	Dhamodharan U, Ponjayanthi B, Sireesh D, Bhakkiyalakshmi E and Ramkumar KM: Association of single-nucleotide polymorphisms of the KEAP1 gene with the risk of various human diseases and its functional impact using in silico analysis. Pharmacol Res. 137:205–218. 2018. View Article : Google Scholar : PubMed/NCBI
36	Pintard L, Kurz T, Glaser S, Willis JH, Peter M and Bowerman B: Neddylation and deneddylation of CUL-3 is required to target MEI-1/Katanin for degradation at the meiosis-to-mitosis transition in C. elegans. Curr Biol. 13:911–921. 2003. View Article : Google Scholar : PubMed/NCBI
37	Gray WM, Hellmann H, Dharmasiri S and Estelle M: Role of the Arabidopsis RING-H2 protein RBX1 in RUB modification and SCF function. Plant Cell. 14:2137–2144. 2002. View Article : Google Scholar : PubMed/NCBI
38	Bigenzahn JW, Collu GM, Kartnig F, Pieraks M, Vladimer GI, Heinz LX, Sedlyarov V, Schischlik F, Fauster A and Rebsamen M: LZTR1 is a regulator of RAS ubiquitination and signaling. Science. 362:1171–1177. 2018. View Article : Google Scholar : PubMed/NCBI
39	Wang Y, Zhang J, Zhang P, Zhao Z, Huang Q, Yun D, Chen J, Chen H, Wang C and Lu D: LZTR1 inactivation promotes MAPK/ERK pathway activation in glioblastoma by stabilizing oncoprotein RIT1. bioRxiv. Mar 15–2020.(Epub ahead of print).
40	Nacak TG, Leptien K, Fellner D, Augustin HG and Kroll J: The BTB-kelch protein LZTR-1 is a novel Golgi protein that is degraded upon induction of apoptosis. J Biol Chem. 281:5065–5071. 2006. View Article : Google Scholar : PubMed/NCBI
41	Adams J, Kelso R and Cooley L: The kelch repeat superfamily of proteins: Propellers of cell function. Trends Cell Biol. 10:17–24. 2000. View Article : Google Scholar : PubMed/NCBI
42	Chen Z, Wasney GA, Picaud S, Filippakopoulos P, Vedadi M, D'Angiolella V and Bullock AN: Identification of a PGXPP degron motif in dishevelled and structural basis for its binding to the E3 ligase KLHL12. Open Biol. 10:2000412020. View Article : Google Scholar : PubMed/NCBI
43	Heng LZ, Kennedy J, Smithson S, Newbury-Ecob R and Churchill A: New macular findings in individuals with biallelic KLHL7 gene mutation. BMJ Open Ophthalmol. 4:e0002342019. View Article : Google Scholar : PubMed/NCBI
44	Narahara S, Sakai E, Kadowaki T, Yamaguchi Y, Narahara H, Okamoto K, Asahina I and Tsukuba T: KBTBD11, a novel BTB-Kelch protein, is a negative regulator of osteoclastogenesis through controlling Cullin3-mediated ubiquitination of NFATc1. Sci Rep. 9:35232019. View Article : Google Scholar : PubMed/NCBI
45	Gao C, Pallett MA, Croll TI, Smith GL and Graham SC: Molecular basis of cullin-3 (Cul3) ubiquitin ligase subversion by vaccinia virus protein A55. J Biol Chem. 294:6416–6429. 2019. View Article : Google Scholar : PubMed/NCBI
46	Nakaguma M, Jorge AA and Arnhold IJ: Noonan syndrome associated with growth hormone deficiency with biallelic LZTR1 variants. Genet Med:. 21:2602019. View Article : Google Scholar : PubMed/NCBI
47	Jacquinet A, Bonnard A, Capri Y, Martin D, Sadzot B, Bianchi E, Servais L, Sacré JP, Cavé H and Verloes A: Oligo-astrocytoma in LZTR1-related Noonan syndrome. Eur J Med Genet. 63:1036172020. View Article : Google Scholar : PubMed/NCBI
48	Deiller C, Van-Gils J, Zordan C, Tinat J, Loiseau H, Fabre T, Delleci C, Cohen J, Vidaud M, Parfait B, et al: Coexistence of schwannomatosis and glioblastoma in two families. Eur J Med Genet. 62:1036802019. View Article : Google Scholar : PubMed/NCBI
49	Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A and Plotkin SR: Clinical features of schwannomatosis: A retrospective analysis of 87 patients. Oncologist. 17:1317–1322. 2012. View Article : Google Scholar : PubMed/NCBI
50	Kehrer-Sawatzki H, Farschtschi S, Mautner VF and Cooper DN: The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum Genet. 136:129–148. 2017. View Article : Google Scholar : PubMed/NCBI
51	Mansouri S, Suppiah S, Mamatjan Y, Paganini I, Liu JC, Karimi S, Patil V, Nassiri F, Singh O, Sundaravadanam Y, et al: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. Acta Neuropathol. 141:101–116. 2020. View Article : Google Scholar : PubMed/NCBI
52	Simanshu DK, Nissley DV and McCormick F: RAS proteins and their regulators in human disease. Cell. 170:17–33. 2017. View Article : Google Scholar : PubMed/NCBI
53	Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, et al: Germline KRAS mutations cause Noonan syndrome. Nat Genet. 38:331–336. 2006. View Article : Google Scholar : PubMed/NCBI
54	Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, Kurosawa K, Ogata T, Takada F, Yano M, Ando T, et al: Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet. 93:173–180. 2013. View Article : Google Scholar : PubMed/NCBI
55	Castel P, Cheng A, Cuevas-Navarro A, Everman DB, Papageorge AG, Simanshu DK, Tankka A, Galeas J, Urisman A and McCormick F: RIT1 oncoproteins escape LZTR1-mediated proteolysis. Science. 363:1226–1230. 2019. View Article : Google Scholar : PubMed/NCBI
56	Umeki I, Niihori T, Abe T, Kanno SI, Okamoto N, Mizuno S, Kurosawa K, Nagasaki K, Yoshida M, Ohashi H, et al: Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes. Hum Genet. 138:21–35. 2019. View Article : Google Scholar : PubMed/NCBI
57	Abe T, Umeki I, Kanno SI, Inoue SI, Niihori T and Aoki Y: LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases. Cell Death Differ. 27:1023–1035. 2020. View Article : Google Scholar : PubMed/NCBI
58	Steklov M, Pandolf S, Baietti MF, Batiuk A, Carai P, Najm P, Zhang M, Jang H, Renzi F, Cai Y, et al: Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination. Science. 362:1177–1182. 2018. View Article : Google Scholar : PubMed/NCBI
59	Zinatizadeh MR, Momeni SA, Zarandi PK, Chalbatani GM, Dana H, Mirzaei HR, Akbari ME and Miri SR: The role and function of Ras-association domain family in cancer: A Review. Genes Dis. 6:378–384. 2019. View Article : Google Scholar : PubMed/NCBI
60	Tidyman WE and Rauen KA: Pathogenetics of the RASopathies. Hum Mol Genet. 25:R123–R132. 2016. View Article : Google Scholar : PubMed/NCBI
61	Malaquias AC and Jorge AAL: Activation of the MAPK pathway (RASopathies) and partial growth hormone insensitivity. Mol Cell Endocrinol. 519:1110402021. View Article : Google Scholar : PubMed/NCBI
62	Humphries B, Wang Z and Yang C: Rho GTPases: Big Players in Breast Cancer Initiation, Metastasis and Therapeutic Responses. Cells. 9:21672020. View Article : Google Scholar : PubMed/NCBI
63	Lavoie H, Gagnon J and Therrien M: ERK signalling: A master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 21:607–632. 2020. View Article : Google Scholar : PubMed/NCBI
64	Moore AR, Rosenberg SC, McCormick F and Malek S: RAS-targeted therapies: Is the undruggable drugged? Nat Rev Drug Discov. 19:533–552. 2020. View Article : Google Scholar : PubMed/NCBI
65	Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, König R, et al: A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet. 42:27–29. 2010. View Article : Google Scholar : PubMed/NCBI
66	Higgins EM, Bos JM, Mason-Suares H, Tester DJ, Ackerman JP, MacRae CA, Sol-Church K, Gripp KW, Urrutia R and Ackerman MJ: Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy. JCI Insight. 2:e912252017. View Article : Google Scholar : PubMed/NCBI
67	Flex E, Jaiswal M, Pantaleoni F, Martinelli S, Strullu M, Fansa EK, Caye A, De Luca A, Lepri F, Dvorsky R, et al: Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum Mol Genet. 23:4315–4327. 2014. View Article : Google Scholar : PubMed/NCBI
68	Ratner N and Miller SJ: A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 15:290–301. 2015. View Article : Google Scholar : PubMed/NCBI
69	Dunnett-Kane V, Burkitt-Wright E, Blackhall FH, Malliri A, Evans DG and Lindsay CR: Germline and sporadic cancers driven by the RAS pathway: Parallels and contrasts. Ann Oncol. 31:873–883. 2020. View Article : Google Scholar : PubMed/NCBI
70	Johnston JJ, van der Smagt JJ, Rosenfeld JA, Pagnamenta AT, Alswaid A, Baker EH, Blair E, Borck G, Brinkmann J, Craigen W, et al Members of the Undiagnosed Diseases Network, : Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants. Genet Med. 20:1175–1185. 2018. View Article : Google Scholar : PubMed/NCBI
71	Aoki Y, Niihori T, Inoue S and Matsubara Y: Recent advances in RASopathies. J Hum Genet. 61:33–39. 2016. View Article : Google Scholar : PubMed/NCBI
72	Motta M, Fidan M, Bellacchio E, Pantaleoni F, Schneider-Heieck K, Coppola S, Borck G, Salviati L, Zenker M, Cirstea IC, et al: Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling. Hum Mol Genet. 28:1007–1022. 2019. View Article : Google Scholar : PubMed/NCBI
73	Pagnamenta AT, Kaisaki PJ, Bennett F, Burkitt-Wright E, Martin HC, Ferla MP, Taylor JM, Gompertz L, Lahiri N, Tatton-Brown K, et al DDD Study, : Delineation of dominant and recessive forms of LZTR1-associated Noonan syndrome. Clin Genet. 95:693–703. 2019. View Article : Google Scholar : PubMed/NCBI
74	Rodriguez-Viciana P, Oses-Prieto J, Burlingame A, Fried M and McCormick F: A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell. 22:217–230. 2006. View Article : Google Scholar : PubMed/NCBI
75	Young LC, Hartig N, Muñoz-Alegre M, Oses-Prieto JA, Durdu S, Bender S, Vijayakumar V, Vietri Rudan M, Gewinner C, Henderson S, et al: An MRAS, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth. Mol Cell. 52:679–692. 2013. View Article : Google Scholar : PubMed/NCBI
76	Shi GX, Cai W and Andres DA: Rit subfamily small GTPases: Regulators in neuronal differentiation and survival. Cell Signal. 25:2060–2068. 2013. View Article : Google Scholar : PubMed/NCBI
77	Khalil A and Nemer G: The potential oncogenic role of the RAS-like GTP-binding gene RIT1 in glioblastoma. Cancer Biomark. 29:509–519. 2020. View Article : Google Scholar : PubMed/NCBI
78	Van R, Cuevas-Navarro A, Castel P and McCormick F: The molecular functions of RIT1 and its contribution to human disease. Biochem J. 477:2755–2770. 2020. View Article : Google Scholar : PubMed/NCBI
79	Song Z, Liu T, Chen J, Ge C, Zhao F, Zhu M, Chen T, Cui Y, Tian H, Yao M, et al: HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib. Cancer Lett. 460:96–107. 2019. View Article : Google Scholar : PubMed/NCBI
80	Venugopal V and Romero CJ: Endocrine complications of Noonan syndrome beyond short stature. Pediatr Endocrinol Rev. 16 (Suppl 2):465–470. 2019.PubMed/NCBI
81	Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI
82	Jin J, Ang XL, Shirogane T and Wade Harper J: Identification of substrates for F-box proteins. Methods Enzymol. 399:287–309. 2005. View Article : Google Scholar : PubMed/NCBI
83	Li S, Balmain A and Counter CM: A model for RAS mutation patterns in cancers: Finding the sweet spot. Nat Rev Cancer. 18:767–777. 2018. View Article : Google Scholar : PubMed/NCBI
84	Pierpont ME, Brueckner M, Chung WK, Garg V, Lacro RV, McGuire AL, Mital S, Priest JR, Pu WT, Roberts A, et al American Heart Association Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Genomic and Precision Medicine, : Genetic Basis for Congenital Heart Disease: Revisited: A scientific statement from the American Heart Association. Circulation. 138:e653–e711. 2018. View Article : Google Scholar : PubMed/NCBI
85	Tajan M, Paccoud R, Branka S, Edouard T and Yart A: The RASopathy family: Consequences of germline activation of the RAS/MAPK pathway. Endocr Rev. 39:676–700. 2018. View Article : Google Scholar : PubMed/NCBI
86	Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mossé YP, Nakagawara A, Parareda A, Scollon SR, Schneider KW, Skalet AH, et al: Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 23:e98–e106. 2017. View Article : Google Scholar : PubMed/NCBI
87	Dolecek TA, Propp JM, Stroup NE and Kruchko C: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 14 (Suppl 5):v1–v49. 2012. View Article : Google Scholar : PubMed/NCBI
88	Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, et al: Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26:756–784. 2012. View Article : Google Scholar : PubMed/NCBI
89	Lee E, Yong RL, Paddison P and Zhu J: Comparison of glioblastoma (GBM) molecular classification methods. Semin Cancer Biol. 53:201–211. 2018. View Article : Google Scholar : PubMed/NCBI
90	Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, et al: Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA. 102:5814–5819. 2005. View Article : Google Scholar : PubMed/NCBI
91	Mischel PS, Nelson SF and Cloughesy TF: Molecular analysis of glioblastoma: Pathway profiling and its implications for patient therapy. Cancer Biol Ther. 2:242–247. 2003. View Article : Google Scholar : PubMed/NCBI
92	Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, Aldape K, Cha S and Kuo MD: Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci USA. 105:5213–5218. 2008. View Article : Google Scholar : PubMed/NCBI
93	Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 9:157–173. 2006. View Article : Google Scholar : PubMed/NCBI
94	Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, et al: The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet. 45:1141–1149. 2013. View Article : Google Scholar : PubMed/NCBI
95	Lein PJ, Guo X, Shi GX, Moholt-Siebert M, Bruun D and Andres DA: The novel GTPase Rit differentially regulates axonal and dendritic growth. J Neurosci. 27:4725–4736. 2007. View Article : Google Scholar : PubMed/NCBI
96	Cai W, Rudolph JL, Harrison SM, Jin L, Frantz AL, Harrison DA and Andres DA: An evolutionarily conserved Rit GTPase-p38 MAPK signaling pathway mediates oxidative stress resistance. Mol Biol Cell. 22:3231–3241. 2011. View Article : Google Scholar : PubMed/NCBI
97	Shi GX and Andres DA: Rit contributes to nerve growth factor-induced neuronal differentiation via activation of B-Raf-extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades. Mol Cell Biol. 25:830–846. 2005. View Article : Google Scholar : PubMed/NCBI
98	Shi GX, Han J and Andres DA: Rin GTPase couples nerve growth factor signaling to p38 and b-Raf/ERK pathways to promote neuronal differentiation. J Biol Chem. 280:37599–37609. 2005. View Article : Google Scholar : PubMed/NCBI
99	Rusyn EV, Reynolds ER, Shao H, Grana TM, Chan TO, Andres DA and Cox AD: Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways. Oncogene. 19:4685–4694. 2000. View Article : Google Scholar : PubMed/NCBI
100	Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA. 68:820–823. 1971. View Article : Google Scholar : PubMed/NCBI
101	Ren R: Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 5:172–183. 2005. View Article : Google Scholar : PubMed/NCBI
102	Garcia-Horton A and Lipton JH: Treatment outcomes in chronic myeloid leukemia: Does one size fit all? J Natl Compr Canc Netw. 18:1421–1428. 2020. View Article : Google Scholar : PubMed/NCBI
103	Crisà E, Nicolosi M, Ferri V, Favini C, Gaidano G and Patriarca A: Atypical chronic myeloid leukemia: Where are we now? Int J Mol Sci. 21:68622020. View Article : Google Scholar
104	Braun TP, Eide CA and Druker BJ: Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 37:530–542. 2020. View Article : Google Scholar : PubMed/NCBI
105	Vetrie D, Helgason GV and Copland M: The leukaemia stem cell: Similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 20:158–173. 2020. View Article : Google Scholar : PubMed/NCBI
106	Evans DG, Bowers NL, Tobi S, Hartley C, Wallace AJ, King AT, Lloyd SK, Rutherford SA, Hammerbeck-Ward C, Pathmanaban ON, et al: Schwannomatosis: A genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 89:1215–1219. 2018. View Article : Google Scholar : PubMed/NCBI
107	Kehrer-Sawatzki H, Farschtschi S, Mautner VF and Cooper DN: The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum Genet. 136:129–148. 2017. View Article : Google Scholar : PubMed/NCBI
108	Smith MJ, Isidor B, Beetz C, Williams SG, Bhaskar SS, Richer W, O'Sullivan J, Anderson B, Daly SB, Urquhart JE, et al: Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology. 84:141–147. 2015. View Article : Google Scholar : PubMed/NCBI
109	Yamamoto GL, Aguena M, Gos M, Hung C, Pilch J, Fahiminiya S, Abramowicz A, Cristian I, Buscarilli M, Naslavsky MS, et al: Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. J Med Genet. 52:413–421. 2015. View Article : Google Scholar : PubMed/NCBI
110	Lamlum H, Ilyas M, Rowan A, Clark S, Johnson V, Bell J, Frayling I, Efstathiou J, Pack K, Payne S, et al: The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: A new facet to Knudson's ‘two-hit’ hypothesis. Nat Med. 5:1071–1075. 1999. View Article : Google Scholar : PubMed/NCBI
111	Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F and Wesseling P: Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet. 80:805–810. 2007. View Article : Google Scholar : PubMed/NCBI
112	Paganini I, Chang VY, Capone GL, Vitte J, Benelli M, Barbetti L, Sestini R, Trevisson E, Hulsebos TJ, Giovannini M, et al: Expanding the mutational spectrum of LZTR1 in schwannomatosis. Eur J Hum Genet. 23:963–968. 2015. View Article : Google Scholar : PubMed/NCBI
113	Smith MJ, Pathmanaban ON, Coope DJ, King AT and Evans DG: Comment on: SMARCB1 gene mutation predisposes to earlier development of glioblastoma: A case report of familial GBM. J Neuropathol Exp Neurol. 80:289–290. 2021. View Article : Google Scholar : PubMed/NCBI
114	Fonkem E, Peng S, Berens M and Mukherjee S: Authors' reply: SMARCB1 gene mutation predisposes to earlier development of glioblastoma: A case report of familial GBM. J Neuropathol Exp Neurol. 80:290–291. 2021. View Article : Google Scholar : PubMed/NCBI
115	Louvrier C, Pasmant E, Briand-Suleau A, Cohen J, Nitschké P, Nectoux J, Orhant L, Zordan C, Goizet C, Goutagny S, et al: Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Neuro Oncol. 20:917–929. 2018. View Article : Google Scholar : PubMed/NCBI
116	Maurer GW, Malita A, Nagy S, Koyama T, Werge TM, Halberg KA, Texada MJ and Rewitz K: Analysis of genes within the schizophrenia-linked 22q11.2 deletion identifies interaction of night owl/LZTR1 and NF1 in GABAergic sleep control. PLoS Genet. 16:e10087272020. View Article : Google Scholar : PubMed/NCBI
117	Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M and Collins F: The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 63:851–859. 1990. View Article : Google Scholar : PubMed/NCBI
118	Liu P, Wang Y and Li X: Targeting the untargetable KRAS in cancer therapy. Acta Pharm Sin B. 9:871–879. 2019. View Article : Google Scholar : PubMed/NCBI
119	Buscail L, Bournet B and Cordelier P: Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 17:153–168. 2020. View Article : Google Scholar : PubMed/NCBI
120	Krastev DB and Buchholz F: Ribosome biogenesis and p53: Who is regulating whom? Cell Cycle. 10:3417–3418. 2011. View Article : Google Scholar : PubMed/NCBI
121	Weiss RA: A perspective on the early days of RAS research. Cancer Metastasis Rev. 39:1023–1028. 2020. View Article : Google Scholar : PubMed/NCBI
122	Uprety D and Adjei AA: KRAS: From undruggable to a druggable cancer target. Cancer Treat Rev. 89:1020702020. View Article : Google Scholar : PubMed/NCBI
123	Chen H and Zhao J: KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC). Thorac Cancer. 11:3425–3435. 2020. View Article : Google Scholar : PubMed/NCBI
124	Goulding RE, Chenoweth M, Carter GC, Boye ME, Sheffield KM, John WJ, Leusch MS, Muehlenbein CE, Li L, Jen MH, et al: KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis. Cancer Treat Res Commun. 24:1002002020. View Article : Google Scholar : PubMed/NCBI
125	Passiglia F, Malapelle U, Del Re M, Righi L, Pagni F, Furlan D, Danesi R, Troncone G and Novello S: KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. Eur J Cancer. 137:57–68. 2020. View Article : Google Scholar : PubMed/NCBI
126	Matthew B, Juliati R and Field SJ: GOLPH3 links the Golgi, DNA damage, and cancer. Cancer Res. 75:624–627. 2015. View Article : Google Scholar : PubMed/NCBI